A large biotechnology company headquartered in the USA is continuously looking to expand its pipeline through external partnerships and is open to many types of collaboration, including e.g. collaborative research, equity investments, licensing, or M&A. The company considers opportunities from around the globe.
The firm is currently focused on neurodegenerative diseases, neuromuscular disorders, pain, neuroimmunology/-inflammation, other rare neurological diseases, and adjacencies to neurology such as ophthalmology; and other rare and orphan diseases. The firm is seeking platform technologies (e.g. gene therapy/editing) as well as single therapeutic assets that facilitate the identification and validation of new therapeutic targets, biomarkers and patient segmentation strategies. The firm considers projects from post-lead identification and pre-IND to late clinical stages, with an increased interest in Phase Ib and later projects.
Along this line, the company is also interested in diagnostic tools to utilize biomarkers of interest early in clinical trials. The firm is modality agnostic with respect to therapeutic approaches. The firm evaluates deal opportunities on a case-by-case basis, considering a wide range of opportunities from early academic partnerships to M&A.
The firm principally evaluates opportunities based on three key criteria: transformative (‘moonshot’) solution to unmet medical need, sound scientific basis, and clear clinical development and regulatory pathways.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment